Actively Recruiting
Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study
Led by National Cancer Center, Japan · Updated on 2024-03-25
60
Participants Needed
1
Research Sites
279 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will assess minimal residual disease (MRD) in HER2-positive early breast cancer patients in Asian countries. The purpose is to evaluate the relation between the detection rate of MRD and recurrence.
CONDITIONS
Official Title
Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age of 20 years or older at the date of registration.
- Histological diagnosis of HER2-positive invasive breast carcinoma.
- Patients scheduled for neoadjuvant chemotherapy followed by surgery.
- Clinical Stage IIA-IIIC.
- Known hormone receptor status.
- Signed informed consent.
You will not qualify if you...
- Any other malignancy within 5 years prior to registration, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the esophagus, stomach, colon, or cervix.
- Bilateral synchronous breast cancer.
- History of breast cancer.
- Pregnancy at registration.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Cancer Center Hospital, Japan
Chuo-ku, Tokyo, Japan, 104-0045
Actively Recruiting
Research Team
Y
Yuki Kojima, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here